Genmab A/S (NASDAQ:GMAB) Cut to Hold at Zacks Research

Zacks Research downgraded shares of Genmab A/S (NASDAQ:GMAB) from a strong-buy rating to a hold rating in a research note published on Tuesday,Zacks.com reports.

Several other equities research analysts have also recently commented on GMAB. Wall Street Zen raised shares of Genmab A/S from a “hold” rating to a “buy” rating in a research report on Monday, July 28th. HC Wainwright raised their target price on shares of Genmab A/S from $35.00 to $36.00 and gave the stock a “buy” rating in a research report on Friday, August 15th. Finally, Truist Financial raised their target price on shares of Genmab A/S from $45.00 to $46.00 and gave the stock a “buy” rating in a research report on Tuesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.60.

Genmab A/S Stock Performance

Shares of Genmab A/S stock opened at $24.42 on Tuesday. The stock has a market capitalization of $15.67 billion, a price-to-earnings ratio of 12.27, a price-to-earnings-growth ratio of 6.98 and a beta of 0.95. The company has a fifty day moving average of $21.90 and a 200-day moving average of $21.04. Genmab A/S has a 52-week low of $17.24 and a 52-week high of $27.94.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.15. The business had revenue of $925.00 million during the quarter, compared to analysts’ expectations of $5.77 billion. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. Genmab A/S has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Institutional Trading of Genmab A/S

A number of institutional investors and hedge funds have recently bought and sold shares of GMAB. Orbis Allan Gray Ltd increased its stake in Genmab A/S by 102.8% during the 1st quarter. Orbis Allan Gray Ltd now owns 5,710,741 shares of the company’s stock valued at $111,816,000 after purchasing an additional 2,895,179 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its stake in Genmab A/S by 152.3% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 3,454,378 shares of the company’s stock valued at $71,367,000 after purchasing an additional 2,084,966 shares in the last quarter. Deep Track Capital LP bought a new stake in Genmab A/S during the 4th quarter valued at about $41,740,000. Two Sigma Advisers LP increased its stake in Genmab A/S by 168.8% during the 4th quarter. Two Sigma Advisers LP now owns 1,653,500 shares of the company’s stock valued at $34,509,000 after purchasing an additional 1,038,400 shares in the last quarter. Finally, Two Sigma Investments LP increased its stake in Genmab A/S by 122.2% during the 4th quarter. Two Sigma Investments LP now owns 1,706,364 shares of the company’s stock valued at $35,612,000 after purchasing an additional 938,455 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.